5.57k followers • 31 symbols Watchlist by Yahoo Finance
Follow this list to discover and track large drug and biotechnology companies.
Curated by Yahoo Finance
Follow this list to discover and track large drug and biotechnology companies. These companies develop specialty drugs and treatments for various diseases and medical conditions. Although there are risks associated with the success of the drug, those that succeed tend to have a strong series of earnings growth over a period of time, especially when they are backed by patents.
The list includes stocks priced at $5 or more with a three month average daily trading volume in excess of 200,000 shares. This list is generated daily and sorted by market cap; the gains are based on the latest closing price and limited to the top 30 stocks that meet the criteria.
This watchlist is similar to a discontinued watchlist called Battling Cancer.
Yahoo Finance employs sophisticated algorithms to monitor and detect trends in the Global Financial Markets. We bring these insights to you in the form of watchlists.
Find other winning investment ideas with the Yahoo Finance Screener.How are these weighted?
The stocks in this watchlist are weighted equally.
|Watchlist||Change today||1-month return||1-year return||Total return|
|Biotech and Drug Stocks||+0.48%||-||-||-|
|Symbol||Company name||Last price||Change||% change||Market time||Volume||Avg vol (3-month)||Market cap|
|JNJ||Johnson & Johnson||167.84||-0.92||-0.55%||4:00 pm GMT-5||5.85M||7.47M||441.86B|
|RHHBY||Roche Holding AG||50.3||+0.82||+1.66%||3:59 pm GMT-5||2.23M||751.03k||347.59B|
|PFE||Pfizer Inc.||54.95||-0.59||-1.06%||4:02 pm GMT-5||27.07M||42.70M||308.43B|
|ABBV||AbbVie Inc.||135.87||+2.35||+1.76%||4:02 pm GMT-5||10.48M||6.39M||240.20B|
|LLY||Eli Lilly and Company||244.12||-5.55||-2.22%||4:02 pm GMT-5||2.89M||3.07M||233.52B|
|NVO||Novo Nordisk A/S||96.32||-3.24||-3.25%||4:00 pm GMT-5||2.46M||1.21M||219.57B|
|MRK||Merck & Co., Inc.||81.38||+0.06||+0.07%||4:02 pm GMT-5||9.48M||13.78M||205.56B|
|NVS||Novartis AG||90.55||-0.07||-0.08%||4:00 pm GMT-5||1.58M||2.44M||202.90B|
|AZN||AstraZeneca PLC||58.85||+0.75||+1.29%||4:00 pm GMT-5||5.01M||4.54M||182.36B|
|BMY||Bristol-Myers Squibb Company||64.93||+0.33||+0.51%||4:00 pm GMT-5||10.30M||13.07M||144.12B|
|AMGN||Amgen Inc.||235.36||+4.51||+1.95%||4:00 pm GMT-5||3.01M||2.78M||132.57B|
|SNY||Sanofi||51.93||+1.20||+2.37%||4:00 pm GMT-5||1.98M||1.58M||130.53B|
|GSK||GlaxoSmithKline plc||45.47||+0.41||+0.91%||4:00 pm GMT-5||3.40M||4.02M||114.40B|
|ZTS||Zoetis Inc.||206.18||-0.82||-0.40%||4:03 pm GMT-5||2.21M||1.66M||97.55B|
|GILD||Gilead Sciences, Inc.||71.77||-0.11||-0.15%||4:00 pm GMT-5||8.34M||7.15M||90.03B|
|MRNA||Moderna, Inc.||204.73||-5.44||-2.59%||4:00 pm GMT-5||10.17M||11.56M||83.01B|
|REGN||Regeneron Pharmaceuticals, Inc.||615.24||-0.87||-0.14%||4:00 pm GMT-5||791.99k||754.19k||66.16B|
|BAYRY||Bayer Aktiengesellschaft||15.06||+0.53||+3.65%||3:59 pm GMT-5||556.45k||588.69k||59.61B|
|VRTX||Vertex Pharmaceuticals Incorporated||234.06||+7.48||+3.30%||4:00 pm GMT-5||2.18M||1.88M||59.51B|
|WXXWY||WuXi Biologics (Cayman) Inc.||23.97||+0.80||+3.45%||3:56 pm GMT-5||138.22k||226.44k||50.96B|
|BNTX||BioNTech SE||196||-6.99||-3.44%||4:00 pm GMT-5||2.86M||3.34M||47.53B|
|TAK||Takeda Pharmaceutical Company Limited||14.75||+0.19||+1.30%||4:00 pm GMT-5||2.15M||2.54M||45.95B|
|BIIB||Biogen Inc.||239.3||+2.63||+1.11%||4:00 pm GMT-5||1.77M||1.58M||35.15B|
|BGNE||BeiGene, Ltd.||238.64||+2.46||+1.04%||4:00 pm GMT-5||213.33k||256.68k||25.35B|
|SGEN||Seagen Inc.||137.09||+0.30||+0.22%||4:00 pm GMT-5||811.33k||810.77k||25.07B|
|GMAB||Genmab A/S||35.7||+0.84||+2.41%||4:00 pm GMT-5||626.36k||433.77k||23.48B|
|HZNP||Horizon Therapeutics Public Limited Company||91.1||+0.70||+0.77%||4:00 pm GMT-5||2.61M||1.57M||20.66B|
|CTLT||Catalent, Inc.||108.24||-1.74||-1.58%||4:03 pm GMT-5||1.29M||1.06M||18.53B|
|VTRS||Viatris Inc.||15.22||+0.20||+1.33%||4:00 pm GMT-5||5.77M||10.20M||18.41B|
|ALNY||Alnylam Pharmaceuticals, Inc.||148.5||+0.50||+0.34%||4:00 pm GMT-5||457.13k||798.58k||17.76B|
Dove soap maker Unilever signalled on Monday it would pursue a deal for GlaxoSmithKline's consumer health business, calling it a "strong strategic fit" after its 50-billion-pound approach ($68.4 billion) was rejected. The update comes after GSK confirmed over the weekend that it had rejected the Unilever offer for its consumer healthcare business, which is home to brands such as Sensodyne toothpaste and Emergen-C vitamin supplement. "The acquisition would create scale and a growth platform for the combined portfolio in the U.S., China and India, with further opportunities in other emerging markets," Unilever said, pointing to synergies in the oral care and vitamin supplements business.
President Emmanuel Macron will on Monday tout 21 new foreign investment projects in France and a booming economy as proof his economic reforms have been bearing fruit less than three months before a presidential election in which he is expected to run. During a visit to Alsace in the east, Macron will announce a 300-million-euro ($342 million) industrial project by German chemical giant BASF, one of 21 new projects worth 4 billion euros and 10,000 jobs as part of a drive to attract foreign investors, his office said. U.S. drugmaker Pfizer also announced on Monday a 520 million euros investment plan in France.
The pharmaceutical giant GlaxoSmithKline said Saturday it has rejected an unsolicited 50 billion-pound ($68.4 billion) bid from Unilever for its consumer healthcare goods unit, a joint venture it controls in a partnership with Pfizer.